AA43279 acts as an inactivation blocker and appears efficient to functionally counteract Nav1.1 haploinsufficiency in a zebrafish model of Dravet syndrome (Frederiksen et al., 2017; Weuring et al., 2020). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.